News
REVBW
0.0099
0.00%
0.00
Weekly Report: what happened at REVB last week (0817-0821)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 08/20 21:06
Revelation Biosciences Grants Performance-Based Executive Stock Awards
TipRanks · 08/19 21:29
Revelation Biosciences Selected Avance Clinical To Serve As CRO For Phase 2/3 Adaptive-Design TITAN Study For Evaluating Gemini In Patients With Acute Kidney Injury
Benzinga · 08/19 13:05
Weekly Report: what happened at REVB last week (0810-0814)?
Weekly Report · 08/17 10:20
Weekly Report: what happened at REVB last week (0803-0807)?
Weekly Report · 08/10 10:15
Revelation Biosciences (REVB) Gets a Buy from Roth MKM
TipRanks · 08/07 18:25
Revelation Biosciences GAAP EPS of -$0.87
Seeking Alpha · 08/07 13:38
Revelation Biosciences Q2 EPS $(0.87) Beats $(0.88) Estimate
Benzinga · 08/06 21:18
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in July 2026
Seeking Alpha · 08/03 13:45
Revelation Biosciences announces results from market assessment for Gemini
TipRanks · 08/03 13:15
Revelation Biosciences Cites Independent Market Assessment Indicating A $94B Total Addressable Market For Its Gemini Kidney Treatment
Benzinga · 08/03 13:03
Weekly Report: what happened at REVB last week (0727-0731)?
Weekly Report · 08/03 10:15
Weekly Report: what happened at REVB last week (0720-0724)?
Weekly Report · 07/27 10:19
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 07/21 15:05
Weekly Report: what happened at REVB last week (0713-0717)?
Weekly Report · 07/20 10:16
Revelation Biosciences Adopts Stockholder Rights Protection Plan
TipRanks · 07/13 21:12
Weekly Report: what happened at REVB last week (0706-0710)?
Weekly Report · 07/13 10:18
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock
Benzinga · 07/10 20:07
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Barchart · 07/10 15:05
More
Webull provides a variety of real-time REVBW stock news. You can receive the latest news about Rvltn Bioscnc through multiple platforms. This information may help you make smarter investment decisions.
About REVBW
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).